Guselkumab is a recombinant human IgG1 monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). This antibody exhibits high affinity for IL-23, with dissociation constants (Kd) of 3.3 pmol/L for human IL-23 and 1.9 pmol/L for IL-23 derived from cynomolgus monkeys. By binding to the IL-23p19 subunit, Guselkumab effectively inhibits the production of cytokines that are downstream in the IL-23 signaling pathway. This mechanism of action makes Guselkumab particularly useful in the study of psoriatic arthritis, providing a valuable tool for research into the pathophysiology and potential treatment of this condition.
Guselkumab is a recombinant human IgG1 monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). This antibody exhibits high affinity for IL-23, with dissociation constants (Kd) of 3.3 pmol/L for human IL-23 and 1.9 pmol/L for IL-23 derived from cynomolgus monkeys. By binding to the IL-23p19 subunit, Guselkumab effectively inhibits the production of cytokines that are downstream in the IL-23 signaling pathway. This mechanism of action makes Guselkumab particularly useful in the study of psoriatic arthritis, providing a valuable tool for research into the pathophysiology and potential treatment of this condition.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
